Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
The Pharmalot View
STAT+

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

  • Ed Silverman

By Ed Silverman July 19, 2021

Reprints
FDA stop sign
Sarah Silbiger/Getty Images

Never mind the conflicts, there are drugs to approve.

In a sorry turn of events, the Food and Drug Administration is facing a confidence-draining debacle thanks to its controversial approval of a pricey Alzheimer’s drug for which evidence appears suspect, at best.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Create a display name to comment

This name will appear with your comment

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Ohio attorney general accuses pharmacy benefit managers of drug…
Ohio attorney general accuses pharmacy benefit managers of drug price fixing
Pharmalittle: FDA proposes more rigorous cancer drug trials for…
Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds…
California judge deals GSK a setback as first Zantac…
California judge deals GSK a setback as first Zantac lawsuit will now go to trial
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings

Recommended Stories